Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 7

Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update)

Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update)

NICE Clinical Guidelines - National Collaborating Centre for Chronic Conditions (UK)

Version: 2008

Evidence Tables

Dietary adherence for the vegan group was defined as the absence of meat, poultry, fish, dairy, or egg intake, saturated fat ≤ and total fat ≤25% of energy, and average daily cholesterol intake ≤50mg.

Oral glucose control therapies (2): other oral agents and exenatide

The recommendations in this guideline on thiazolidinediones (R40 to R43, chapter 10), GLP-1 mimetic (exenatide) (R44 to R46, chapter 10) and insulin therapy (R49 to R55), chapter 11) have been updated and replaced by NICE short clinical guideline 87 ‘Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes’ (available at www.nice.org.uk/CG87shortguideline). This short guideline contains details of the methods and evidence used to develop the updated recommendations. Chapter 10 and 11 should be read in conjunction with the short clinical guideline 87.

Oral glucose control therapies (1): metformin, insulin secretagogues, and acarbose

Glucose control deteriorates continually with time in most people with Type 2 diabetes – it is not a chronic stable condition., This is known to be due to progressive failure of insulin secretion. Accordingly therapy has to be stepped up with time, one drug added to another until such time as only exogenous insulin replacement will suffice.

Glucose control: insulin therapy

The recommendations in this guideline on thiazolidinediones (R40 to R43, chapter 10), GLP-1 mimetic (exenatide) (R44 to R46, chapter 10) and insulin therapy (R49 to R55), chapter 11) have been updated and replaced by NICE short clinical guideline 87 ‘Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes’ (available at www.nice.org.uk/CG87shortguideline). This short guideline contains details of the methods and evidence used to develop the updated recommendations. Chapter 10 and 11 should be read in conjunction with the short clinical guideline 87.

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...